Journal of Dispersion Science and Technology,
Journal Year:
2024,
Volume and Issue:
45(12), P. 2249 - 2264
Published: May 5, 2024
Isoniazid
(INH)
is
amongst
the
first-line
antibiotics
that
have
been
employed
for
treatment
of
Tuberculosis
(TB).
Despite
its
potent
anti-tubercular
action,
susceptibility
to
rapid
hepatic
first-pass
metabolism
and
elimination
largely
limits
oral
bioavailability,
has
associated
with
induction
drug
resistance
adverse
effects.
This
presents
study
aims
at
development
evaluation
unique
mannosylated
INH
loaded
solid
lipid
nanoparticles
(Mn-INH-SLNs)
TB.
The
Mn-INH-SLNs
demonstrated
a
particle
size
466
±
11
nm,
which
was
acceptable
macrophage
targeting
had
%
entrapment
efficiency
80.41
1.37%
(n
=
6).
dissolution
studies
depicted
dual-phase
release
profile,
i.e.,
burst
followed
by
sustained
release,
revealing
best
fit
Korsmeyer-Peppas
model.
MTT
assay
(cytotoxicity
study)
performed
utilizing
J774A.1
cells
optimized
deemed
them
be
safe
nontoxic.
Mannosylated
SLNs
tagged
coumarin-6
(C6
–
an
established
fluorescent
marker)
showed
substantially
high
intracellular
internalization
(1.11-folds)
when
analyzed
through
flow
cytometric
analysis
(FACS).
in
vivo
pharmacokinetic
following
per-oral
administration
rats
significant
rise
relative
bioavailability
(∼5.5-folds)
compared
pure
solution.
bio-distribution
(drug
disposition)
exhibited
greater
lung
accumulation
(2.13-folds)
comparison
unconjugated
INH-SLNs
(Un-INH-SLNs).
promising
results
depict
targeted-optimized
may
propitious
tool
fight
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
13(19)
Published: April 5, 2024
Glioblastoma
(GBM),
the
most
prevalent
and
aggressive
primary
malignant
brain
tumor,
exhibits
profound
immunosuppression
demonstrates
a
low
response
rate
to
current
immunotherapy
strategies.
Manganese
cations
(Mn
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
35(21)
Published: March 12, 2023
Glucose-responsive
insulin-delivery
platforms
that
are
sensitive
to
dynamic
glucose
concentration
fluctuations
and
provide
both
rapid
prolonged
insulin
release
have
great
potential
control
hyperglycemia
avoid
hypoglycemia
diabetes.
Here,
biodegradable
charge-switchable
phytoglycogen
nanoparticles
capable
of
glucose-stimulated
engineered.
The
"nanosugars"
bearing
glucose-sensitive
phenylboronic
acid
groups
amine
moieties
allow
effective
complexation
with
(≈95%
loading
capacity)
form
nanocomplexes.
A
single
subcutaneous
injection
nanocomplexes
shows
a
efficient
response
challenge
in
two
distinct
diabetic
mouse
models,
resulting
optimal
blood
levels
(below
200
mg
dL-1
)
for
up
13
h.
morphology
the
is
found
be
key
controlling
extended
glucose-regulated
delivery
vivo.
These
studies
reveal
injected
enabled
mouse,
bioavailability,
pharmacokinetics,
safety
profiles.
results
highlight
promising
strategy
development
glucose-responsive
system
based
on
natural
nanosugar.
